Metagenomi Therapeutics, Inc. (MGX): Total Assets
$221.10M
As of 2025-12-31
$173.70M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $221.10M | -31.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $324.60M | -11.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $364.84M | n/a | 2025-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗